Genomic diversity of colorectal cancer: Changing landscape and emerging targets

Table 1 Ongoing combination targeted therapy trials for colorectal cancer

Agent(s)	Class of agent	Phase	Trial number1	Misc
MEK162 + Panitumumab	MEK tyrosine kinase inhibitor, anti-EGFR mAb	Ib/II	NCT01927341	mCRC with mutant or wild-type RAS tumors
Dabrafenib + Trametinib + Panitumumab + 5-Fluorouracil	BRAF tyrosine kinase inhibitor, MEK tyrosine kinase inhibitor, anti-EGFR mAb	I/II	NCT01750918	BRAF-V600E mutant + and in pts with secondary resistance to anti-EGFR mAb
LGX818 + Cetuximab ± BYL719	BRAF tyrosine kinase inhibitor, anti-EGFR mAb, PI3K tyrosine kinase inhibitor	I/II	NCT01719380	BRAF mutant mCRC
Irinotecan + Cetuximab ± Vemurafenib	anti-EGFR mAb, BRAF tyrosine kinase inhibitor	II	NCT02164916	BRAF mutant mCRC
Neratinib + Cetuximab	HER-2 tyrosine kinase inhibitor, anti-EGFR mAb	I/II	NCT01960023	KRAS, NRAS, BRAF, PIK3CA wild type

¹Utilizing the NCT number, clinical trial information can be obtained at https://clinicaltrials.gov. mAb: Monoclonal antibody; mCRC: Metastatic colorectal cancer; EGFR: Epidermal growth factor receptor; PIK3CA: Phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha; BRAF: v-Raf murine sarcoma viral oncogene homolog B.